158144-80-0

Usage

Chemical class

t-butyl ester derivative of piperidinecarboxylic acid

Molecular weight

275.39 g/mol

Physical state

white to off-white solid at room temperature

Solubility

soluble in organic solvents such as acetone and ethyl acetate

Uses

organic synthesis, pharmaceutical research, and potential applications in the development of pharmaceutical drugs, as well as other industrial uses.

Upstream product

• 158144-79-7 tert-butyl 4-cyano-4-phenylpiperidine-1-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 51304-58-6 4-cyano-4-phenylpiperidine hydrochloride 

Downstream Products

• 167262-68-2 N-(t-butyloxycarbonyl)-4-phenylpiperidine-4-carboxylic acid 
• 716358-34-8 tert-butyl 4-[(E/Z)-2-methoxyethenyl]-4phenylpiperidine-1-carboxylate 
• 1292306-44-5 ethyl 5-(4-phenylpiperidin-4-yl)pentanoate hydrochloride 
• 1292306-46-7 C₂₁H₃₁NO₄ 
• 716360-31-5 tert-butyl 4-(3-oxopropyl)-4-phenylpiperidine-1-carboxylate 
• 1292306-47-8 C₂₃H₃₃NO₄ 
• 1292360-02-1 C₂₃H₃₅NO₄ 
• 167853-55-6 4-[3-(3,5-Bis-trifluoromethyl-phenyl)-3-hydroxy-propyl]-4-phenyl-piperidine-1-carboxylic acid tert-butyl ester 
• 167853-54-5 4-[3-(3,5-Bis-trifluoromethyl-phenyl)-3-oxo-propyl]-4-phenyl-piperidine-1-carboxylic acid tert-butyl ester 
• 172734-33-7 4-hydroxy-4-phenylpiperidine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF

The present invention provides a compound of Formula (1) as described herein or a pharmaceutically acceptable salt, solvate or ester thereof. The compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and methods of treating cancer using the same.

[2-(4-Phenyl-4-piperidinyl)ethyl]amine based CCR5 antagonists: derivatizations at the N-terminal of the piperidine ring

Several series of CCR5 antagonists have been discovered by derivatization at the N-terminal of the piperidine ring of the core template 2. Some derivatives exhibited potent inhibition against HIV-1infection. The pharmacokinetic properties of the lead comp

Discovery of bioavailable 4,4-disubstituted piperidines as potent ligands of the chemokine receptor 5 and inhibitors of the human immunodeficiency virus-1

We describe robust chemical approaches toward putative CCR5 scaffolds designed in our laboratories. Evaluation of analogues in the 125I-[MIP-1β] binding and Ba-L-HOS antiviral assays resulted in the discovery of 64 and 68 in the 4,4-disubstitited piperidine class H, both potent CCR5 ligands (pIC50 = 8.30 and 9.00, respectively) and HIV-1 inhibitors (pIC50 = 7.80 and 7.84, respectively, in Ba-L-HOS assay). In addition, 64 and 68 were bioavailable in rodents, establishing them as lead molecules for further optimization toward CCR5 clinical candidates.

Synthesis of functionalized nitrogen heterocycles by radical decarboxylation of β- and γ-amino acids

Iodinated or oxygenated nitrogen heterocycles are obtained by radical decarboxylation of β- and γ-amino acids. This mild, versatile reaction is applied to the synthesis of bioactive products, such as 4-arylpiperidines, hydroxylated piperidines, and new antifungal agents.

CCR5 ANTAGONISTS AS THERAPEUTIC AGENTS

The present invention relates to compounds of formula (I) or pharmaceutically acceptable derivatives thereof, useful in the treatment or prophylaxis of CCR5-related diseases and disorders, for example, in the inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).

4,4-Disubstituted piperidine high-affinity NK1 antagonists: Structure- activity relationships and in vivo activity

Previously reported studies from these laboratories described the design of a novel series of high-affinity NK1 antagonists based on the 4,4- disubstituted piperidine ring system. Further structure-activity studies have now established that for high NK1 affinity the benzyl ether side chain must be 3,5-disubstituted and highly lipophilic, the optimal side chain being the 3,5-bis(trifluoromethyl)benzyl ether, 12 (hNK1 IC50 = 0.95 nM). Additional studies have shown that this class of NK1 antagonist tolerates a wider range of substituents on the piperidine nitrogen, including acyl (38) (hNK1 IC50 = 5.3 nM) and sulfonyl (39) (hNK1 IC50 = 5.7 nM) derivatives. Following preliminary pharmacokinetic analysis, two compounds (32 and 43) were selected for in vivo study in the resiniferotoxin-induced vascular leakage model, both showing excellent profiles (ID50 = 0.22 and 0.28 mg/kg, respectively).